Compare Fastly Inc (FSLY) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Moderna, Inc. — how do they compare? Fastly Inc trades at $29.85 (market cap $4.54B), while Moderna, Inc. trades at $63.92 (market cap $25.42B). The key difference: Moderna, Inc. is far larger — about 5.6× Fastly Inc's market cap, and Fastly Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| FSLY | MRNA | |
|---|---|---|
Market Cap | $4.54B | $25.42B |
Sector | Technology | Health |
52-Week High | $33.50 | $81.80 |
52-Week Low | $6.91 | $22.36 |
Enterprise Value | $4.61B | $21.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $30.02, up 4.31% today, showing strong momentum following consecutive earnings beats. The stock is approaching resistance at $30 with bullish technical signals from moving averages. Revenue growth accelerated to 23% in Q2 2026, reaching $624M annually, though the company remains unprofitable with a -19.5% net margin. Recent news highlights security expansion and AI demand driving optimism.
The outlook balances improving fundamentals against persistent losses. Earnings momentum and raised 2026 guidance support upside potential, but negative cash flow and high valuation multiples pose risks. Analyst consensus is cautious with a $28.25 target below current price, suggesting limited near-term appreciation despite operational progress.
Moderna (MRNA) trades at $63.65, up 5.09% on the day, with a bullish technical signal from moving averages and recent FDA approval of its mRNA flu vaccine mFLUSIVA for adults 50+. Despite negative net income margins and declining revenue since 2022, the company beat Q2 2026 EPS estimates and maintains a diversified pipeline in flu, oncology, and rare diseases. Cash flow improved in 2025 with positive net cash flow of $668 million.
The outlook hinges on pipeline execution beyond COVID-19, with growth opportunities in new vaccine approvals but significant risks from persistent losses and competitive pressures. Analyst consensus is cautious with a hold-heavy rating and $54.33 price target below the current price, indicating skepticism about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
